Rabeprazole Sodium
Tier B — Position earlyRabeprazole Sodium
Targets：Proton pump
Brand：Aciphex, Aciphex Sprinkle, Pariet, Aciphex/Pariet, Achipex
Indications (approved)：Gastro-oesophageal reflux disease, Peptic oesophagitis, Duodenal ulcer, Gastric ulcer, Zollinger-Ellison syndrome, Heartburn, Helicobacter pylori infection, Helicobacter infection
Regional status
Synthetic routes & intermediates5 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
| Code | CAS No. | Intermediate |
|---|---|---|
| RABE-001 | 1589-49-7 | 3-methoxypropan-1-ol |
| RABE-002 | 59886-90-7 | 4-chloro-2,3-dimethylpyridine 1-oxide |
| RABE-003 | 117977-18-1 | 4-(3-methoxypropoxy)-2,3-dimethylpyridine 1-oxide |
| RABE-004 | 117977-20-5 | 2-(chloromethyl)-4-(3-methoxypropoxy)-3-methylpyridine |
| RABE-005 | 583-39-1 | 1H-benzo[d]imidazole-2-thiol |
| RABE-006 | 117977-21-6 | 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)thio)-1H-benzo[d]imidazole |
| Code | CAS No. | Intermediate |
|---|---|---|
| RABE-005 | 583-39-1 | 1H-benzo[d]imidazole-2-thiol |
| RABE-006 | 117977-21-6 | 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)thio)-1H-benzo[d]imidazole |
| RABE-007 | 153259-31-5 | 2-(chloromethyl)-4-(3-methoxypropoxy)-3-methylpyridine hydrochloride |
| RABE-008 | 117976-89-3 | 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole |
| Code | CAS No. | Intermediate |
|---|---|---|
| RABE-006 | 117977-21-6 | 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)thio)-1H-benzo[d]imidazole |
| Code | CAS No. | Intermediate |
|---|---|---|
| RABE-005 | 583-39-1 | 1H-benzo[d]imidazole-2-thiol |
| RABE-009 | 117977-20-5 | 2-(chloromethyl)-4-(3-methoxypropoxy)-3-methylpyridine |
| Code | CAS No. | Intermediate |
|---|---|---|
| RABE-004 | 117977-20-5 | 2-(chloromethyl)-4-(3-methoxypropoxy)-3-methylpyridine |
| RABE-005 | 583-39-1 | 1H-benzo[d]imidazole-2-thiol |
| RABE-008 | 117976-89-3 | 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole |
| RABE-010 | 924663-39-8 | 2-(chloromethyl)-4-(3-methoxypropoxy)-3-methylpyridine 1-oxide |
Frequently asked questions
What are the approved indications of Rabeprazole Sodium?
Approved indications include: Gastro-oesophageal reflux disease, Peptic oesophagitis, Duodenal ulcer, Gastric ulcer, Zollinger-Ellison syndrome, Heartburn, Helicobacter pylori infection, Helicobacter infection.
When does the Rabeprazole Sodium patent expire?
No public expiry year is available for Rabeprazole Sodium yet; this page updates once verified.
How many synthesis routes are recorded for Rabeprazole Sodium?
5 synthesis routes are recorded; the shortest is 1 steps with / total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy Rabeprazole Sodium intermediates?
All intermediates in Rabeprazole Sodium routes have CAS profiles — you can submit an RFQ per CAS and it enters the Unibest matching pool.
How do I get a quote for Rabeprazole Sodium intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29